Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18722910 | 0.88 | TGFBR1 (0.34) | TGFBR1MAPK14PPARGCYP1A2CYP2D6 | |
| SCHEMBL17682037 | 0.88 | TGFBR1 (0.34) | TGFBR1MAPK14PPARGCYP1A2CYP2D6 | |
| SCHEMBL17645213 | 0.79 | TGFBR1 (0.37) | TGFBR1MAPK14F2 | |
| SCHEMBL17645372 | 0.77 | TGFBR1 (0.49) | TGFBR1 | |
| SCHEMBL30725992 | 0.77 | KDM4E (0.38) | TGFBR1MAPK14DGAT1CYP1A2CYP2D6 | |
| SCHEMBL17645163 | 0.76 | TGFBR1 (0.37) | TGFBR1MAPK14PTGS2 | |
| SCHEMBL31074732 | 0.76 | CYP1A2 (0.35) | TGFBR1MAPK14DGAT1CYP1A2CYP2D6 | |
| SCHEMBL28408249 | 0.76 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL17645224 | 0.74 | TGFBR1 (0.37) | TGFBR1MAPK14PTGS2 | |
| SCHEMBL17645375 | 0.72 | TGFBR1 (0.45) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204377-B1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | TGFBR1 1/4885MAPK14 1182/4885F11 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.